Skip to Content

Join the 'Non-Small Cell Lung Cancer' group to help and get support from people like you.

Non-Small Cell Lung Cancer News

Related terms: Cancer, Lung, Non-Small Cell, Lung Cancer, Non-Small Cell, NSCLC

Weight May Influence Outcomes After Lung Cancer Surgery

Posted 14 days ago by Drugs.com

TUESDAY, Jan. 26, 2016 – Lung cancer surgery patients are most likely to have complications and to die if they're either too thin or fat, a new study suggests. The study included more than 41,000 people who had lung cancer surgery between 2009 and 2014. Patients were categorized according to their body mass index (BMI) – an estimate of body fat based on weight and height. While the study couldn't prove cause-and-effect, people who were either underweight or severely obese had the highest rates of complications and death following surgery, according to the study. The findings were to be presented Tuesday at the annual meeting of the Society of Thoracic Surgeons in Phoenix. Weight "is associated with a patient's overall physiology and health, but overweight people need to have more muscle to carry the extra weight around," study co-leader Dr. Trevor Williams of the University of ... Read more

Related support groups: Surgery, Obesity, Lung Cancer, Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Vascular Surgery, Bronchogenic Carcinoma

Smokers With Pneumonia at Risk for Lung Cancer: Study

Posted 14 Jan 2016 by Drugs.com

THURSDAY, Jan. 14, 2016 – Smokers diagnosed with pneumonia may be at greater risk for developing lung cancer, a new study suggests. Researchers found that 9 percent of smokers admitted to the hospital for pneumonia developed lung cancer within one year, so they recommend early screening for the disease among heavy smokers treated for pneumonia. "Lung cancer is truly aggressive. The only chance of recuperation is if it's caught before it begins to cause any symptoms at all. The idea is to find the tumor well in advance," said study leader Dr. Daniel Shepshelovich, from Tel Aviv University's Sackler Faculty of Medicine and the Rabin Medical Center, in Israel. "Previous studies have shown that a low-dose radiation CT scan conducted once a year on heavy smokers has the potential to lower lung cancer mortality rates," he said in a university news release. "But this requires huge resources, ... Read more

Related support groups: Smoking, Pneumonia, Smoking Cessation, Nicotine, Lung Cancer, Non-Small Cell Lung Cancer, Nicorette, Nicoderm CQ, Nicotrol Inhaler, Small Cell Lung Cancer, Commit, Habitrol, Streptococcal Pneumonia, Nicotrol NS, Nicotrol TD, Nicorelief, Nicorette DS, ProStep, Bronchogenic Carcinoma

Teikoku Pharma USA, Inc. Announces FDA Approval of Docetaxel Injection, Non-Alcohol Formula

Posted 30 Dec 2015 by Drugs.com

San Jose, Calif. - December 28, 2015 - Teikoku Pharma USA (TPU) announced today that the U.S. Food and Drug Administration ("FDA") has approved Docetaxel Injection, Non-Alcohol Formula ("Docetaxel Injection") for the treatment of breast cancer, non-small cell lung cancer, prostate cancer, gastric adenocarcinoma, and head and neck cancer. Teikoku entered into an exclusive licensing agreement with Eagle Pharmaceuticals Inc. ("Eagle Pharmaceuticals") in October 2015 to market, sell and distribute Docetaxel Injection in the U.S. The main difference, compared to other docetaxel formulations, is that Docetaxel Injection is the first non-alcohol formulation approved in the U.S. Further differentiating it from some of the currently marketed docetaxel formulations is that Teikoku's Docetaxel Injection: Requires no prior dilution with a diluent and is ready to add to the infusion solution; and ... Read more

Related support groups: Breast Cancer, Prostate Cancer, Non-Small Cell Lung Cancer, Head and Neck Cancer, Gastric Cancer, Docetaxel

Keytruda May Help Fight Tough-to-Treat Lung Cancer

Posted 21 Dec 2015 by Drugs.com

SATURDAY, Dec. 19, 2015 – The immune therapy drug Keytruda (pembrolizumab) may extend the lives of people with advanced lung cancer, a new study finds. Keytruda is commonly used to treat other tumor types, and made headlines recently after it helped former President Jimmy Carter fight off brain cancer. In this study, researchers compared Keytruda to the chemotherapy drug docetaxel in more than 1,000 patients with non-small cell lung cancer. All of the patients were battling tumors that had progressed even after chemotherapy. Non-small cell lung cancer is the leading form of the disease. All of the patients' tumors produced a protein called PD-L1, which can shield the tumor from immune system attack, according to a team led by Dr. Roy Herbst, professor of medicine at Yale University School of Medicine. Among patients with the highest amounts of PD-L1, those who received Keytruda lived ... Read more

Related support groups: Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Taxotere, Docetaxel, Keytruda, Docefrez

Alecensa Approved for Lung Cancer Tied to Gene Mutation

Posted 21 Dec 2015 by Drugs.com

FRIDAY, Dec. 11, 2015 – Alecensa (alectinib) has been approved by the U.S. Food and Drug administration to treat anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer, the agency said Friday in a news release. This type of cancer often spreads to the brain. The pill is sanctioned for instances of worsening disease after patients take a standard therapy called Xalkori (crizotinib), or if they are unable to tolerate Xalkori. More than 221,000 people in the United States are projected to develop lung cancer this year, and more than 158,000 will die from it, according to the National Cancer Institute. ALK gene mutations are involved in about 5 percent of cases of non-small cell lung cancer, the FDA said. Alecensa is designed to block the effects of the ALK protein, thereby preventing these cancer cells from growing and spreading. The most common side effects of the drug are ... Read more

Related support groups: Non-Small Cell Lung Cancer, Alectinib, Alecensa

FDA Approves Alecensa (alectinib) for ALK-Positive Non-Small Cell Lung Cancer

Posted 12 Dec 2015 by Drugs.com

December 11, 2015 – The U.S. Food and Drug Administration today approved Alecensa (alectinib) to treat people with advanced (metastatic) ALK-positive non-small cell lung cancer (NSCLC) whose disease has worsened after, or who could not tolerate treatment with, another therapy called Xalkori (crizotinib). Lung cancer is the leading cause of cancer death in the United States, with an estimated 221,200 new diagnoses and 158,040 deaths in 2015, according to the National Cancer Institute. An ALK (anaplastic lymphoma kinase) gene mutation can occur in several different types of cancer cells, including lung cancer cells. ALK gene mutations are present in about 5 percent of patients with NSCLC. In metastatic cancer, the disease spreads to new parts of the body. In ALK-positive NSCLC metastatic patients, the brain is a common place for the disease to spread. “Today’s approval provides a new th ... Read more

Related support groups: Non-Small Cell Lung Cancer, Alectinib, Alecensa

Portrazza Approved for Advanced Lung Cancer

Posted 12 Dec 2015 by Drugs.com

TUESDAY, Nov. 24, 2015 – Portrazza (necitumumab), in combination with two other chemotherapy drugs, has been approved by the U.S. Food and Drug Administration to treat advanced squamous non-small cell lung cancer, the agency said Tuesday in a news release. Lung cancer is the leading cause of cancer death in the United States. More than 221,000 cases are expected to be diagnosed in the U.S. this year, and more than 158,000 people are projected to die from the disease, the FDA said. Portrazza, approved for people who haven't had a previous therapy for squamous NSCLC, is designed to block a protein that's frequently found on such tumors, the agency explained. The drug was evaluated in combination with two other drugs, gemcitabine and cisplatin. Those who took the three-drug combination lived for an average of 11.5 months, compared to 9.9 months among those who took the other two drugs ... Read more

Related support groups: Non-Small Cell Lung Cancer, Necitumumab, Portrazza

FDA Approves Portrazza (necitumumab) for Advanced Squamous Non-Small Cell Lung Cancer

Posted 1 Dec 2015 by Drugs.com

November 24, 2015 – The U.S. Food and Drug Administration today approved Portrazza (necitumumab) in combination with two forms of chemotherapy to treat patients with advanced (metastatic) squamous non-small cell lung cancer (NSCLC) who have not previously received medication specifically for treating their advanced lung cancer. Lung cancer is the leading cause of cancer death in the United States, with an estimated 221,200 new diagnoses and 158,040 deaths in 2015. The most common type of lung cancer, non-small cell lung cancer, is further divided into two main types named for the kinds of cells found in the cancer – squamous cell and non-squamous cell (which includes adenocarcinoma). “Lung cancer tumors can be varied, so treatment options need to be tailored to the specific type of lung cancer in the patient,” said Richard Pazdur, M.D., director of the Office of Hematology and Oncol ... Read more

Related support groups: Non-Small Cell Lung Cancer, Necitumumab, Portrazza

FDA Approves Tagrisso (osimertinib) for EGFR T790M Mutation-Positive Non-Small Cell Lung Cancer

Posted 16 Nov 2015 by Drugs.com

Today, the U.S. Food and Drug Administration granted accelerated approval for an oral medication to treat patients with advanced non-small cell lung cancer (NSCLC). Tagrisso (osimertinib) is now approved for patients whose tumors have a specific epidermal growth factor receptor (EGFR) mutation (T790M) and whose disease has gotten worse after treatment with other EGFR-blocking therapy. Lung cancer is the leading cause of cancer death in the United States, with an estimated 221,200 new diagnoses and 158,040 deaths in 2015, according to the National Cancer Institute. The most common type of lung cancer, NSCLC occurs when cancer cells form in the tissues of the lung. The EGFR gene is a protein involved in the growth and spread of cancer cells. “Our understanding of the molecular basis of lung cancer and reasons these cancers become resistant to prior treatments is rapidly evolving,” said R ... Read more

Related support groups: Non-Small Cell Lung Cancer, Osimertinib, Tagrisso

Lung Cancer Surgery Rates Differ Widely Between States

Posted 13 Nov 2015 by Drugs.com

FRIDAY, Nov. 13, 2015 – Rates of surgery to cure lung cancer vary greatly across the United States, a new study finds. Researchers analyzed data from patients in 38 states and the District of Columbia who were diagnosed with early stage non-small cell lung cancer between 2007 and 2011. Non-small cell lung cancer is the most common type of lung cancer. It can potentially be cured by surgery if it's detected at an early stage before it spreads, the study authors pointed out. The highest rates of surgery to cure lung cancer were seen in Massachusetts, New Jersey and Utah, at about 75 percent each. The lowest rate was in Wyoming, where patients were 25 percent less likely to have curative surgery than those in the top three states, the findings showed. "We do not have a uniform quality of health care in this country," said Dr. Helmneh Sineshaw, health services researcher with the American ... Read more

Related support groups: Surgery, Lung Cancer, Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Vascular Surgery, Bronchogenic Carcinoma

High-Risk Lung Cancer Patients May Benefit From Surgery

Posted 10 Nov 2015 by Drugs.com

TUESDAY, Nov. 10, 2015 – Surgery to remove part of the lung can be a safe and effective treatment option for people with early stage lung cancer, even those traditionally considered "high-risk," a new study finds. Previous research had suggested that high-risk patients are more likely to have complications or to die after lung surgery. People aged 60 and older, long-term smokers, and people who have other health problems are considered high-risk for partial lung removal surgery, the researchers said. One in five patients with early stage non-small-cell lung cancer is deemed high-risk or ineligible for lung surgery, according to the study, which was published online Nov. 10 in The Annals of Thoracic Surgery. But the new findings show these patients shouldn't be denied surgery, because they may benefit from it, study leader Dr. Manu Sancheti, from Emory University School of Medicine in ... Read more

Related support groups: Surgery, Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Surgical Prophylaxis, Bronchogenic Carcinoma

FDA Expands Approved Use of Opdivo (nivolumab) in Advanced Lung Cancer

Posted 9 Oct 2015 by Drugs.com

October 9, 2015 – The U.S. Food and Drug Administration today approved Opdivo (nivolumab) to treat patients with advanced (metastatic) non-small cell lung cancer whose disease progressed during or after platinum-based chemotherapy. Lung cancer is the leading cause of cancer death in the United States, with an estimated 221,200 new diagnoses and 158,040 deaths in 2015. The most common type of lung cancer, non-small cell lung cancer (NSCLC), is further divided into two main types named for the kinds of cells found in the cancer – squamous cell and non-squamous cell (which includes adenocarcinoma).Opdivo works by targeting the cellular pathway known as PD-1/PD-L1 (proteins found on the body’s immune cells and some cancer cells). By blocking this pathway, Opdivo may help the body’s immune system fight the cancer cells. Earlier this year, the FDA approved Opdivo to treat patients with advan ... Read more

Related support groups: Non-Small Cell Lung Cancer, Opdivo, Nivolumab

Keytruda Approved for Leading Form of Lung Cancer

Posted 2 Oct 2015 by Drugs.com

FRIDAY, Oct. 2, 2015 – Keytruda (pembrolizumab) has been approved by the U.S. Food and Drug Administration to treat advanced cases of the most common type of lung malignancy, non-small cell lung cancer (NSCLC). The drug is approved for people whose tumors produce a protein called PD-L1, and whose cancer has lingered despite use of other treatments, the agency said Friday in a news release. Lung cancer is the most common cause of cancer death in the United States, accounting for more than 220,000 cases and more than 158,000 deaths so far this year, the FDA said. Keytruda, in blocking the PD-L1 protein, helps the body better fight this cancer, the FDA explained. The drug was first approved in 2014 to treat advanced melanoma skin cancer. Keytruda's performance in fighting lung cancer was evaluated in clinical studies of 550 people with advanced disease. The most common side effects ... Read more

Related support groups: Lung Cancer, Non-Small Cell Lung Cancer, Pembrolizumab, Keytruda

FDA Approves New Treatment for Lung Cancer

Posted 2 Oct 2015 by Drugs.com

FRIDAY, Oct. 2, 2015 – The U.S. Food and Drug Administration on Friday approved an immunotherapy drug for the treatment of advanced non-small cell lung cancer. Keytruda (pembrolizumab) can be used to treat advanced non-small cell lung cancer in patients whose disease has progressed after previous treatments and who have tumors that express a protein called PD-L1, the agency said. "Today's approval of Keytruda gives physicians the ability to target specific patients who may be most likely to benefit from this drug," Dr. Richard Pazdur, director of the Office of Hematology and Oncology Products in the FDA's Center for Drug Evaluation and Research, said in an agency news release. The Merck & Co. drug was approved for use with a companion diagnostic test that is the first designed to detect PD-L1 expression in non-small cell lung tumors, the FDA said in the news release. By blocking what ... Read more

Related support groups: Lung Cancer, Non-Small Cell Lung Cancer, Pembrolizumab, Keytruda

FDA Approves Keytruda (pembrolizumab) for Advanced Non-Small Cell Lung Cancer

Posted 2 Oct 2015 by Drugs.com

October 2, 2015 – The U.S. Food and Drug Administration today granted accelerated approval for Keytruda (pembrolizumab) to treat patients with advanced (metastatic) non-small cell lung cancer (NSCLC) whose disease has progressed after other treatments and with tumors that express a protein called PD-L1. Keytruda is approved for use with a companion diagnostic, the PD-L1 IHC 22C3 pharmDx test, the first test designed to detect PD-L1 expression in non-small cell lung tumors. Lung cancer is the leading cause of cancer death in the United States, with an estimated 221,200 new diagnoses and 158,040 deaths in 2015, according to the National Cancer Institute. NSCLC is the most common type of lung cancer.“Our growing understanding of underlying molecular pathways and how our immune system interacts with cancer is leading to important advances in medicine,” said Richard Pazdur, M.D., director o ... Read more

Related support groups: Lung Cancer, Non-Small Cell Lung Cancer, Pembrolizumab, Keytruda

Page 1 2 3 4 5 6 7 8 Next

Ask a Question

Further Information

Related Condition Support Groups

Lung Cancer

Related Drug Support Groups

methotrexate, Tarceva, Avastin, Taxol, cisplatin, Xalkori, Taxotere, gemcitabine, Gemzar, view more... cyclophosphamide, capecitabine, Iressa, paclitaxel, Alimta, erlotinib, Cyramza, docetaxel, Abraxane, bevacizumab, gefitinib, Gilotrif, Navelbine, amifostine, pembrolizumab, ramucirumab, crizotinib, cetuximab, Platinol, afatinib, Opdivo, pemetrexed, Keytruda, Methotrexate LPF Sodium, vinorelbine, nivolumab, Trexall, Docefrez, Alecensa, Portrazza, Zykadia, Tagrisso, Ethyol, osimertinib, ceritinib, porfimer, paclitaxel protein-bound, necitumumab, alectinib, Folex PFS, Photofrin, Onxol, Platinol-AQ